The Development Background of Minglu neck pain particles

Minglu neck pain particles is a national first-line drug specially designed for cervical degeneration based on evidence-based medicine of cervical spondylosis, and it is a key scientific research project in National Medical Products Administration. 1998, Conscience (Group) Co., Ltd., a Sino-foreign joint venture, officially declared its national project and participated in 18 scientific research units, including Peking University Third Hospital, the First Affiliated Hospital of the Fourth Military Medical University of the Chinese People's Liberation Army, Liaoning American Food and Drug Administration, Liaoning Medical College, Sun Yat-sen Medical University and PLA 30 1 hospital. The National University of Singapore School of Medicine, the University of Bristol and other major units have given strong support. It lasted for 4 years and was officially accepted by the US Food and Drug Administration in 2002. And obtained the national US Food and Drug Administration (Z20025076), China National Intellectual Property Administration invention patent (patent number ZL02 1 09359.8) and international patent (international patent classification number A6 1K 35/78). Mainly exported to the European market, and turned to domestic sales in 2009.